RxDoctor Payments Data

Haneen Khamag, MD

Internal Medicine · Mission Hills, CANPI 1346538683

Payments from drug & device makers

$1,073in general payments, 2019–2025

Across 23 payments — averaging $46.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$375
  • Abbott$197
  • AbbVie$149
  • Shionogi Inc$145
  • Novo Nordisk$51
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$33
  • plus $123 from 6 others

What the payments were for

  • Food & beverage$1,073100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,073 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$53,010
Medicare patients
123
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$47,054
EntrestoSacubitril/Valsartan27$24,559
OzempicSemaglutide12$16,221
Clonidine11$968
Hydralazine Hcl63$836
Atorvastatin Calcium71$811
Isosorbide Mononitrate ErIsosorbide Mononitrate37$651
Bumetanide16$586
Levothyroxine Sodium38$516
Cefpodoxime Proxetil15$504
Metoprolol Succinate45$502
Midodrine Hcl11$476
Gabapentin34$394
Losartan Potassium36$391
Albuterol Sulfate HfaAlbuterol Sulfate15$369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$20$24,55927 claims
Novo NordiskOzempic$51$16,22112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →